Showing 6971-6980 of 8649 results for "".
- The Vision Council Opens Registration for 2026 Executive Summithttps://modernod.com/news/the-vision-council-opens-registration-for-2026-executive-summit/2484153/The Vision Council announced that registration is open for the 2026 Executive Summit. The 3-day forum will be held January 26-28, 2026, at The Ritz-Carlton, Amelia Island, Florida.
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Nanoscope to Present Long-Term Data for MCO-010 in RP at Euretina and Retina Society 2025https://modernod.com/news/nanoscope-to-present-long-term-data-for-mco-010-in-rp-at-euretina-and-retina-society-2025/2484129/Nanoscope Therapeutics announced it will present new long-term data from its RESTORE follow-up study, REMAIN, at two major international meetings: the 2025 Euretina Congress in Paris and the 2025 Retina Society Annual Scientific Meeting in Chicago.
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- Beyeonics Vision Secures US Patent for Ophthalmic Surgical Visualization Technologyhttps://modernod.com/news/beyeonics-vision-secures-us-patent-for-ophthalmic-surgical-visualization-technology/2482931/Beyeonics Vision announced the issuance of a US patent to protect its core technology for how surgeons visualize the eye during cataract and other ocular procedures. According to Beyeonics, the patent, titled “Systems and Methods for Imaging a
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)